Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Flatiron health record analysis comparing carfilzomib dosing in relapsed/refractory myeloma finds no support for improved outcomes with 2x weekly dosing; K56-1x may best balance efficacy, safety and avoidance of time toxicity.”
Authors: Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Adam Sperling, Larry Anderson Jr, Vincent Rajkumar, Gurbakhash Kaur et al.
More posts featuring Robert Orlowski.